# US 2023/0057987 A1 · Antigen binding proteins specifically binding ct45

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0057987 A1
- Document ID: US20230057987A1
- Status: Published application
- Kind: A1
- Application number: 17/874,711
- Filed: 2022-07-27
- Published: 2023-02-23
- Earliest claimed: 2021-07-27
- Assignees: Immatics Biotechnologies GmbH
- Applicants: Immatics Biotechnologies GmbH
- Inventors: Sara YOUSEF; Fabian BRUNK; Andreas MORITZ; Sebastian BUNK; Claudia WAGNER; Dominik MAURER; Felix UNVERDORBEN
- Web page: https://patentgrep.com/patent/US20230057987A1

## CPC

- C07K 16/3069: {Reproductive system, e.g. ovaria, uterus, testes, prostate}
- A61P 35/00: Antineoplastic agents
- C07K 14/4702: {Regulators; Modulating activity}
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- G01N 33/57595: {involving intracellular compounds}
- C07K 14/70539: {MHC-molecules, e.g. HLA-molecules}
- C07K 2317/30: characterized by aspects of specificity or valency
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/734: Complement-dependent cytotoxicity [CDC]
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention provides an antigen binding protein specifically binding to a CT45 antigenic peptide that is in a complex with a major histocompatibility complex (MHC) protein, wherein the CT45 antigenic peptide comprises or consists of the amino acid sequence of SEQ ID NO: 138 (KIFEMLEGV) and wherein the antigen binding protein comprises a first polypeptide comprising a variable domain VA comprising complementarity determining regions CDRa1, CDRa2 and CDRa3 and a second polypeptide comprising a variable domain VB comprising CDRb1, CDRb2 and CDRb3. Also provided are nucleic acids encoding the antigen binding proteins, vectors comprising the nucleic acids, recombinant cells expressing the antigen binding proteins and pharmaceutical compositions comprising the antigen binding proteins. The invention further provides the antigen binding proteins for use in medicine and a method of producing the antigen binding protein.

## Claims

### Claim 1

An antigen binding protein specifically binding to a CT45 antigenic peptide that is in a complex with a major histocompatibility complex (MHC) protein, wherein the CT45 antigenic peptide comprises or consists of the amino acid sequence of SEQ ID NO: 138 (KIFEMLEGV) and wherein the antigen binding protein comprises a first polypeptide comprising a variable domain VA comprising complementarity determining regions (CDR) CDRa1, CDRa2 and CDRa3 and a second polypeptide comprising a variable domain VB comprising CDRb1, CDRb2 and CDRb3, wherein
1) CDRa1 comprises or consists of the amino acid sequence of SEQ ID NO: 14, CDRa3 comprises or consists of the amino acid sequence of SEQ ID NO: 16, CDRb1 comprises or consists of the amino acid sequence of SEQ ID NO: 19, and CDRb3 comprises or consists of the amino acid sequence of SEQ ID NO: 21,
2) CDRa1 comprises or consists of the amino acid sequence of SEQ ID NO: 24, CDRa3 comprises or consists of the amino acid sequence of SEQ ID NO: 133, CDRb1 comprises or consists of the amino acid sequence of SEQ ID NO: 75, and CDRb3 comprises or consists of the amino acid sequence of SEQ ID NO: 136,
3) CDRa1 comprises or consists of the amino acid sequence of SEQ ID NO: 24, CDRa3 comprises or consists of the amino acid sequence of SEQ ID NO: 63, CDRb1 comprises or consists of the amino acid sequence of SEQ ID NO: 66, and CDRb3 comprises or consists of the amino acid sequence of SEQ ID NO: 68,
4) CDRa1 comprises or consists of the amino acid sequence of SEQ ID NO: 90, CDRa3 comprises or consists of the amino acid sequence of SEQ ID NO: 92, CDRb1 comprises or consists of the amino acid sequence of SEQ ID NO: 66, and CDRb3 comprises or consists of the amino acid sequence of SEQ ID NO: 96,
5) CDRa1 comprises or consists of the amino acid sequence of SEQ ID NO: 2, CDRa3 comprises or consists of the amino acid sequence of SEQ ID NO: 4, CDRb1 comprises or consists of the amino acid sequence of SEQ ID NO: 8, and CDRb3 comprises or consists of the amino acid sequence of SEQ ID NO: 10,
6) CDRa1 comprises or consists of the amino acid sequence of SEQ ID NO: 53, CDRa3 comprises or consists of the amino acid sequence of SEQ ID NO: 55, CDRb1 comprises or consists of the amino acid sequence of SEQ ID NO: 58, and CDRb3 comprises or consists of the amino acid sequence of SEQ ID NO: 60,
7) CDRa1 comprises or consists of the amino acid sequence of SEQ ID NO: 71, CDRa3 comprises or consists of the amino acid sequence of SEQ ID NO: 72, CDRb1 comprises or consists of the amino acid sequence of SEQ ID NO: 75, and CDRb3 comprises or consists of the amino acid sequence of SEQ ID NO: 77,
8) CDRa1 comprises or consists of the amino acid sequence of SEQ ID NO: 99, CDRa3 comprises or consists of the amino acid sequence of SEQ ID NO: 101, CDRb1 comprises or consists of the amino acid sequence of SEQ ID NO: 75, and CDRb3 comprises or consists of the amino acid sequence of SEQ ID NO: 104,
9) CDRa1 comprises or consists of the amino acid sequence of SEQ ID NO: 80, CDRa3 comprises or consists of the amino acid sequence of SEQ ID NO: 82, CDRb1 comprises or consists of the amino acid sequence of SEQ ID NO: 85, and CDRb3 comprises or consists of the amino acid sequence of SEQ ID NO: 87,
10) CDRa1 comprises or consists of the amino acid sequence of SEQ ID NO: 107, CDRa3 comprises or consists of the amino acid sequence of SEQ ID NO: 109, CDRb1 comprises or consists of the amino acid sequence of SEQ ID NO: 112, and CDRb3 comprises or consists of the amino acid sequence of SEQ ID NO: 114,
11) CDRa1 comprises or consists of the amino acid sequence of SEQ ID NO: 125, CDRa3 comprises or consists of the amino acid sequence of SEQ ID NO: 127, CDRb1 comprises or consists of the amino acid sequence of SEQ ID NO: 112, and CDRb3 comprises or consists of the amino acid sequence of SEQ ID NO: 130, or
12) CDRa1 comprises or consists of the amino acid sequence of SEQ ID NO: 117, CDRa3 comprises or consists of the amino acid sequence of SEQ ID NO: 119, CDRb1 comprises or consists of the amino acid sequence of SEQ ID NO: 58, and CDRb3 comprises or consists of the amino acid sequence of SEQ ID NO: 122,
13) CDRa1 comprises or consists of the amino acid sequence of SEQ ID NO: 24, CDRa3 comprises or consists of the amino acid sequence of SEQ ID NO: 35, CDRb1 comprises or consists of the amino acid sequence of SEQ ID NO: 38, and CDRb3 comprises or consists of the amino acid sequence of SEQ ID NO: 40,
14) CDRa1 comprises or consists of the amino acid sequence of SEQ ID NO: 24, CDRa3 comprises or consists of the amino acid sequence of SEQ ID NO: 26, CDRb1 comprises or consists of the amino acid sequence of SEQ ID NO: 29, and CDRb3 comprises or consists of the amino acid sequence of SEQ ID NO: 31, or
15) CDRa1 comprises or consists of the amino acid sequence of SEQ ID NO: 43, CDRa3 comprises or consists of the amino acid sequence of SEQ ID NO: 45, CDRb1 comprises or consists of the amino acid sequence of SEQ ID NO: 48, and CDRb3 comprises or consists of the amino acid sequence of SEQ ID NO: 50,
wherein the antigen binding protein comprises said CDRa1, CDRa3, CDRb1 and CDRb3 sequence(s) with not more than one, two or three amino acid mutations, wherein each of CDRa1, CDRa3, CDRb1 and/or CDRb3 optionally comprise one, two or three amino acid mutations.

### Claim 2 (depends on 1)

The antigen binding protein of claim 1, wherein
1) CDRa2 comprises or consists of the amino acid sequence of SEQ ID NO: 15, and CDRb2 comprises or consists of the amino acid sequence of SEQ ID NO: 20
2) CDRa2 comprises or consists of the amino acid sequence of SEQ ID NO: 25, and CDRb2 comprises or consists of the amino acid sequence of SEQ ID NO: 76,
3) CDRa2 comprises or consists of the amino acid sequence of SEQ ID NO: 25, and CDRb2 comprises or consists of the amino acid sequence of SEQ ID NO: 67,
4) CDRa2 comprises or consists of the amino acid sequence of SEQ ID NO: 91, and CDRb2 comprises or consists of the amino acid sequence of SEQ ID NO: 95,
5) CDRa2 comprises or consists of the amino acid sequence of SEQ ID NO: 3, and CDRb2 comprises or consists of the amino acid sequence of SEQ ID NO: 9,
6) CDRa2 comprises or consists of the amino acid sequence of SEQ ID NO: 54, and CDRb2 comprises or consists of the amino acid sequence of SEQ ID NO: 59,
7) CDRa2 comprises or consists of the amino acid sequence of SEQ ID NO: 15, and CDRb2 comprises or consists of the amino acid sequence of SEQ ID NO: 76,
8) CDRa2 comprises or consists of the amino acid sequence of SEQ ID NO: 100, and CDRb2 comprises or consists of the amino acid sequence of SEQ ID NO: 76,
9) CDRa2 comprises or consists of the amino acid sequence of SEQ ID NO: 81, and CDRb2 comprises or consists of the amino acid sequence of SEQ ID NO: 86,
10) CDRa2 comprises or consists of the amino acid sequence of SEQ ID NO: 108, and CDRb2 comprises or consists of the amino acid sequence of SEQ ID NO: 113,
11) CDRa2 comprises or consists of the amino acid sequence of SEQ ID NO: 126, and CDRb2 comprises or consists of the amino acid sequence of SEQ ID NO: 113,
12) CDRa2 comprises or consists of the amino acid sequence of SEQ ID NO: 118, and CDRb2 comprises or consists of the amino acid sequence of SEQ ID NO: 59,
13) CDRa2 comprises or consists of the amino acid sequence of SEQ ID NO: 25, and CDRb2 comprises or consists of the amino acid sequence of SEQ ID NO: 39,
14) CDRa2 comprises or consists of the amino acid sequence of SEQ ID NO: 25, and CDRb2 comprises or consists of the amino acid sequence of SEQ ID NO: 30, or
15) CDRa2 comprises or consists of the amino acid sequence of SEQ ID NO: 44, and CDRb2 comprises or consists of the amino acid sequence of SEQ ID NO: 49,
wherein the antigen binding protein comprises said CDRa2 and CDRb2 sequence(s) with not more than one, two, three or four amino acid mutations, wherein each of CDRa2 and/or CDRb2 optionally comprise one, two, three or four amino acid mutations.

### Claim 3 (depends on 1)

The antigen binding protein of claim 1, wherein the antigen binding protein is a TCR, optionally wherein the TCR is selected from the group consisting of an α/β TCR, a γ/δ TCR, a single chain TCR, a membrane-bound TCR, a soluble TCR, a monovalent, bivalent or multivalent TCR, a monospecific, bispecific or multispecific TCR, a functional fragment of a TCR, and a fusion protein or chimeric protein comprising a functional fragment of a TCR, optionally wherein the TCR is an α/β TCR or a γ/δ TCR, optionally an α/β TCR.

### Claim 4 (depends on 1)

The antigen binding protein of claim 1, wherein VA comprises or consists of an amino acid sequence selected from the group consisting of SEQ ID NO: 13, 132, 62, 89, 1, 52, 70, 98, 79, 106, 124, 116, 34, 23, and 42, or an amino acid sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 98% or 99% identity to SEQ ID NO: 13, 132, 62, 89, 1, 52, 70, 98, 79, 106, 124, 116, 34, 23, and 42 and comprising the CDRa1, the CDRa2 and the CDRa3; and wherein VB comprises or consists of an amino acid sequence selected from the group consisting of SEQ ID NO: 18, 135, 65, 94, 7, 57, 74, 103, 84, 111, 129, 121, 37, 28 and 47 or an amino acid sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 98% or 99% identity to SEQ ID NO: 18, 135, 65, 94, 7, 57, 74, 103, 84, 111, 129, 121, 37, 28 and 47 and comprising the CDRb1, the CDRb2 and the CDRb3, wherein the CDRa1, the CDRa2, the CDRa3, the CDRb1, the CDRb2 and/or the CDRb3 sequences optionally comprise one, two or three amino acid mutations, optionally amino acid substitutions.

### Claim 5 (depends on 1)

The antigen binding protein of claim 1, further comprising a constant domain, wherein the constant domain comprises or consists of an amino acid sequence selected from the group consisting of SEQ ID NO: 5, 750, 751, 156, 11, 32 and 157, optionally selected from the group consisting of SEQ ID NO: 5, 750, 751, 11 and 32, or an amino acid sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 98% or 99% identity to SEQ ID NO: 5, 750, 751, 156, 11, 32 or 157.

### Claim 6 (depends on 1)

The antigen binding protein of claim 1, wherein the first polypeptide comprises or consists of an amino acid sequence selected from the group consisting of SEQ ID NO: 17, 134, 64, 93, 6, 56, 73, 102, 83, 110, 128, 120, 36, 27, 46 and 158-172, optionally selected from the group consisting of SEQ ID NO:17, 134, 64, 93, 6, 56, 73, 102, 83, 110, 128, 120, 36, 27 and 46, or an amino acid sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 98% or 99% identity to SEQ ID NO:17, 134, 64, 93, 6, 56, 73, 102, 83, 110, 128, 120, 36, 27, 46, or 158-172, and the second polypeptide comprises or consists of an amino acid sequence selected from the group consisting of SEQ ID NO: 22, 137, 69, 97, 12, 61, 78 105, 88, 115, 131, 123, 41, 33, 51 and 173-187, optionally selected from the group consisting of SEQ ID NO: 22, 137, 69, 97, 12, 61, 78 105, 88, 115, 131, 123, 41, 33 and 51, or an amino acid sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 98% or 99% identity to SEQ ID NO: 22, 137, 69, 97, 12, 61, 78 105, 88, 115, 131, 123, 41, 33, 51 or 173-187.

### Claim 7 (depends on 1)

The antigen binding protein of claim 1, wherein the antigen binding protein does not significantly bind to at least 1, at least 2, at least 3, at least 4, at least 5, or all similar peptides selected from the group consisting of SEQ ID NO: 146 (SP-05-0001), SEQ ID NO: 147 (SP-05-0002), SEQ ID NO: 148 (SP-05-0003), SEQ ID NO: 149 (SP-05-0004), SEQ ID NO: 150 (SP-05-0005), SEQ ID NO: 151 (SP-05-0006), SEQ ID NO: 152 (SP-05-0007), SEQ ID NO: 153 (SP-05-0008), SEQ ID NO: 154 (SP-05-0009) and SEQ ID NO: 155 (SP-05-0010), optionally from the group consisting of SEQ ID NO: 146 (SP-05-0001), SEQ ID NO: 147 (SP-05-0002), SEQ ID NO: 148 (SP-05-0003), SEQ ID NO: 150 (SP-05-0005), SEQ ID NO: 151 (SP-05-0006), SEQ ID NO: 152 (SP-05-0007), SEQ ID NO: 153 (SP-05-0008), SEQ ID NO: 154 (SP-05-0009) and SEQ ID NO: 155 (SP-05-0010), optionally from the group consisting of SEQ ID NO: 147 (SP-05-0002), SEQ ID NO: 151 (SP-05-0006), SEQ ID NO: 152 (SP-05-0007) and SEQ ID NO: 155 (SP-05-0010).

### Claim 8 (depends on 1)

The antigen binding protein of claim 1, wherein the antigen binding protein is capable of activating
a CD4+ T cell, in particular a CD4+CD8− T cell, and/or
a CD8+ T cell, in particular a CD8+CD4-T cell, and wherein the antigen binding protein is optionally a TCR, optionally an α/β TCR or γ/δ TCR.

### Claim 9 (depends on 1)

A nucleic acid comprising a sequence encoding the antigen binding protein of claim 1.

### Claim 10 (depends on 9)

A vector comprising the nucleic acid of claim 9.

### Claim 11 (depends on 1)

A host cell comprising the antigen binding protein of claim 1.

### Claim 12 (depends on 1)

A pharmaceutical composition comprising the antigen binding protein of claim 1.

### Claim 13 (depends on 1)

The antigen binding protein of claim 1 for use in medicine, optionally for use in a method of treatment and/or diagnosis of a proliferative disease, in particular cancer.

### Claim 14 (depends on 1)

An in-vitro method of detecting cancer, in particular cancer expressing CT45, in a biological sample comprising:
a) contacting the biological sample with the antigen binding protein of claim 1, and
b) detecting binding of the antigen binding protein to the biological sample.

### Claim 15 (depends on 1)

A method of producing the antigen binding protein, comprising
a) providing a host cell,
b) providing a genetic construct comprising a nucleic acid encoding the antigen binding protein of claim 1,
c) introducing the genetic construct into the host cell, and
d) expressing the genetic construct by the host cell.

### Claim 16 (depends on 2)

The antigen binding protein of claim 2, wherein the antigen binding protein is a TCR, optionally wherein the TCR is selected from the group consisting of an α/β TCR, a γ/δ TCR, a single chain TCR, a membrane-bound TCR, a soluble TCR, a monovalent, bivalent or multivalent TCR, a monospecific, bispecific or multispecific TCR, a functional fragment of a TCR, and a fusion protein or chimeric protein comprising a functional fragment of a TCR, optionally wherein the TCR is an α/β TCR or a γ/δ TCR, optionally an α/β TCR.

### Claim 17 (depends on 2)

The antigen binding protein of claim 2, wherein VA comprises or consists of an amino acid sequence selected from the group consisting of SEQ ID NO: 13, 132, 62, 89, 1, 52, 70, 98, 79, 106, 124, 116, 34, 23, and 42, or an amino acid sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 98% or 99% identity to SEQ ID NO: 13, 132, 62, 89, 1, 52, 70, 98, 79, 106, 124, 116, 34, 23, and 42 and comprising the CDRa1, the CDRa2 and the CDRa3; and wherein VB comprises or consists of an amino acid sequence selected from the group consisting of SEQ ID NO: 18, 135, 65, 94, 7, 57, 74, 103, 84, 111, 129, 121, 37, 28 and 47 or an amino acid sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 98% or 99% identity to SEQ ID NO: 18, 135, 65, 94, 7, 57, 74, 103, 84, 111, 129, 121, 37, 28 and 47 and comprising the CDRb1, the CDRb2 and the CDRb3, wherein the CDRa1, the CDRa2, the CDRa3, the CDRb1, the CDRb2 and/or the CDRb3 sequences optionally comprise one, two or three amino acid mutations, optionally amino acid substitutions.

### Claim 18 (depends on 3)

The antigen binding protein of claim 3, wherein VA comprises or consists of an amino acid sequence selected from the group consisting of SEQ ID NO: 13, 132, 62, 89, 1, 52, 70, 98, 79, 106, 124, 116, 34, 23, and 42, or an amino acid sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 98% or 99% identity to SEQ ID NO: 13, 132, 62, 89, 1, 52, 70, 98, 79, 106, 124, 116, 34, 23, and 42 and comprising the CDRa1, the CDRa2 and the CDRa3; and wherein VB comprises or consists of an amino acid sequence selected from the group consisting of SEQ ID NO: 18, 135, 65, 94, 7, 57, 74, 103, 84, 111, 129, 121, 37, 28 and 47 or an amino acid sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 98% or 99% identity to SEQ ID NO: 18, 135, 65, 94, 7, 57, 74, 103, 84, 111, 129, 121, 37, 28 and 47 and comprising the CDRb1, the CDRb2 and the CDRb3, wherein the CDRa1, the CDRa2, the CDRa3, the CDRb1, the CDRb2 and/or the CDRb3 sequences optionally comprise one, two or three amino acid mutations, optionally amino acid substitutions.

### Claim 19 (depends on 2)

The antigen binding protein of claim 2, further comprising a constant domain, wherein the constant domain comprises or consists of an amino acid sequence selected from the group consisting of SEQ ID NO: 5, 750, 751, 156, 11, 32 and 157, optionally selected from the group consisting of SEQ ID NO: 5, 750, 751, 11 and 32, or an amino acid sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 98% or 99% identity to SEQ ID NO: 5, 750, 751, 156, 11, 32 or 157.

### Claim 20 (depends on 3)

The antigen binding protein of claim 3, further comprising a constant domain, wherein the constant domain comprises or consists of an amino acid sequence selected from the group consisting of SEQ ID NO: 5, 750, 751, 156, 11, 32 and 157, optionally selected from the group consisting of SEQ ID NO: 5, 750, 751, 11 and 32, or an amino acid sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 98% or 99% identity to SEQ ID NO: 5, 750, 751, 156, 11, 32 or 157.
